Clinical Trial Update: Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for XKDCT293, a Nectin-4-targeted CAR-T therapy, in Nectin-4-positive advanced breast cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• XKDCT293 (Nectin-4-CAR-T) (Nectin-4-targeted CAR-T therapy)

Snippet

Sponsor: Shenzhen Celconta Life Science Co., Ltd. | Conditions: Advanced Breast Cancer | Phase 1 | Status: UNKNOWN